IC
LABD icon

Ikarian Capital’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Ikarian Capital’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.72M Buy
105,822
+65,000
+159% +$1.23M 0.14% 105
2025
Q4 		$860K Sell
40,822
-51,137
-56% -$1.39M 0.07% 129
2025
Q3 		$3.72M Buy
+91,959
New +$5.33M 0.38% 71

Other funds holding LABD

CCM
Capstone Capital Management Hong Kong $224M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Ikarian Capital's LABD Position: Q1 2026 in Review

Ikarian Capital increased its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 159% in Q1 2026, buying an estimated $1.23M and bringing the position to 105,822 shares worth $1.72M. The position accounts for 0.14% of the portfolio, ranked #105.

Ikarian Capital first reported a position in LABD in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.72M in Q3 2025. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

  • Ikarian Capital held 105,822 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $1.72M as of Q1 2026.
  • Ikarian Capital bought 65,000 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $1.23M.
  • Direxion Daily S&P Biotech Bear 3X ETF made up 0.14% of Ikarian Capital's portfolio in Q1 2026, its #105 holding.
  • Ikarian Capital first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q3 2025 and has held it in 3 quarters since.
  • Ikarian Capital's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $3.72M in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.